In a report released today, Jason Gerberry from Merrill Lynch maintained a Hold rating on Bristol Myers (BMY), with a price target of $51. The company’s shares closed on Friday at $51.67.
According to TipRanks.com, Gerberry has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.9% and a 38.1% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Cara Therapeutics, Merck & Company, and Eli Lilly & Co.
Currently, the analyst consensus on Bristol Myers is a Moderate Buy with an average price target of $56, an 8.4% upside from current levels. In a report issued on February 11, Guggenheim also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Bristol Myers’ market cap is currently $84.34B and has a P/E ratio of 17.05. The company has a Price to Book ratio of 6.18.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
